Immediately after implantation, all patients received clopidogrel 300 mg ... safe alternative to the bare-metal stent for the treatment of de novo coronary artery lesions. The results of the ...

Thus, after the discontinuation of clopidogrel ... be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis. Daemen's study in 2007 was ...

Newer, more potent P2Y12 inhibitors were shown to be superior to clopidogrel in patients with ACS, including the large portion of these patients receiving coronary stents, and because the trials ...

More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

Peripheral Vascular Disease (PVD) is a common complication for those with diabetes, significantly impacting blood flow and ...

The American College of Cardiology (ACC) and the American Heart Association (AHA), in collaboration with ... in response to recent RCT data showing improvements in stent-related and clinical outcomes.

Second, the irreversible P2Y12 receptor inhibition may be associated with an increased risk of hemorrhagic complications, particularly in patients requiring urgent coronary artery bypass ... including ...

Effient (prasugrel), like clopidogrel, is also a P2Y12 platelet inhibitor. Effient is taken to reduce any blood clots from forming in the heart. This includes individuals who have had stents ...

In unstable patients with CAD and recent stent placement, it becomes necessary to devise protocols ... The current recommendations from the American College of Cardiology and the American Heart ...

Heart testing and various blood tests may also be ordered ... Antiplatelet therapy with aspirin, aspirin plus dipyridamole, or Plavix (clopidogrel) is used to inhibit the formation of abnormal clots ...

TAMPA, Fla., Feb. 26, 2025 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital is the first in the southeastern United States and one of only a handful of ...